Femasys Inc. (FEMY)
NASDAQ: FEMY · Real-Time Price · USD
0.4239
+0.0029 (0.69%)
At close: Apr 17, 2026, 4:00 PM EDT
0.4285
+0.0046 (1.09%)
After-hours: Apr 17, 2026, 7:44 PM EDT
Femasys Employees
As of December 31, 2025, Femasys had 54 total employees, including 51 full-time and 3 part-time employees. The number of employees decreased by 17 or -23.94% compared to the previous year.
Employees
54
Change (1Y)
-17
Growth (1Y)
-23.94%
Revenue / Employee
$42,469
Profits / Employee
-$344,961
Market Cap
25.60M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 54 | -17 | -23.94% | 51 | 3 |
| Dec 31, 2024 | 71 | 37 | 108.82% | 69 | 2 |
| Dec 31, 2023 | 34 | -2 | -5.56% | 32 | 2 |
| Dec 31, 2022 | 36 | 7 | 24.14% | 34 | 2 |
| Dec 31, 2021 | 29 | 3 | 11.54% | 27 | 2 |
| Jun 30, 2021 | 27 | - | - | 25 | 2 |
| Mar 31, 2021 | 26 | - | - | 24 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Harvard Bioscience | 339 |
| Jin Medical International | 273 |
| Retractable Technologies | 227 |
| Bionano Genomics | 97 |
| Precision Optics Corporation | 90 |
| Ekso Bionics Holdings | 55 |
| Nephros | 36 |
| Zentek | 18 |
FEMY News
- 19 days ago - Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination - GlobeNewsWire
- 3 months ago - Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care - GlobeNewsWire
- 4 months ago - Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device - GlobeNewsWire
- 5 months ago - PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment - Business Wire
- 5 months ago - Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million - GlobeNewsWire
- 6 months ago - Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo - GlobeNewsWire